- Home
- HAS vs BBIO Comparison
HAS vs BBIO Comparison
Compare HAS & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HAS | BBIO |
|---|---|---|
| Founded | 1923 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 14.2B |
| IPO Year | 1994 | 2019 |
Fundamental Metrics
Financial Performance| Metric | HAS | BBIO |
|---|---|---|
| Price | $97.24 | $68.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 25 |
| Target Price | ★ $109.73 | $86.33 |
| AVG Volume (30 Days) | 1.6M | ★ 2.3M |
| Earning Date | 05-20-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.98% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,365,900,000.00 | $502,076,000.00 |
| Revenue This Year | $5.38 | $89.45 |
| Revenue Next Year | $6.48 | $73.78 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 13.06 | ★ 126.26 |
| 52 Week Low | $61.19 | $31.77 |
| 52 Week High | $106.98 | $84.94 |
Technical Indicators
Market Signals| Indicator | HAS | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 57.69 | 38.46 |
| Support Level | $86.85 | $61.95 |
| Resistance Level | $98.63 | $68.71 |
| Average True Range (ATR) | 3.04 | 3.88 |
| MACD | 0.24 | -0.85 |
| Stochastic Oscillator | 84.27 | 4.40 |
Price Performance
Historical ComparisonAbout HAS Hasbro Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Peppa Pig, and Magic: The Gathering. The firm acquired EOne in 2019, bolting on popular family properties like Peppa Pig and PJ Masks, and has since divested noncore lines from the tie-up. Furthermore, the addition of Dungeons & Dragons Beyond in 2022 offers the firm access to 19 million digital tabletop players.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.